FDA grants investigational new drug status to BTK inhibitor for immunological disease

The FDA has granted an investigational new drug application from Inmagene Biopharmaceuticals for its Bruton tyrosine kinase inhibitor, IMG-004, to potentially treat immunological diseases, according to a press release.
In its statement, the company said the FDA decision clears the way for the drug candidate, a non-covalent, reversible small-molecule inhibitor that targets BTK, to proceed to a phase 1 clinical trial.
“This is the third [investigational new drug] clearance Inmagene has obtained since the beginning of 2022,” Jonathan Wang, PhD, chairman and CEO of Inmagene, said in the

The FDA has granted an investigational new drug application from Inmagene Biopharmaceuticals for its Bruton tyrosine kinase inhibitor, IMG-004, to potentially treat immunological diseases, according to a press release.
In its statement, the company said the FDA decision clears the way for the drug candidate, a non-covalent, reversible small-molecule inhibitor that targets BTK, to proceed to a phase 1 clinical trial.
“This is the third [investigational new drug] clearance Inmagene has obtained since the beginning of 2022,” Jonathan Wang, PhD, chairman and CEO of Inmagene, said in the